微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 32.87% | 2.64% | -1.02% | 106/159 | 31.52% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 33.21% | 2.5% | 2.03% | 115/159 | 51.8% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 32.55% | 2.17% | -0.46% | 115/159 | 22.98% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 32.7% | 3.06% | 2.09% | 115/159 | 33.39% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 32.03% | -2.54% | -1.15% | 115/159 | 51.73% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 32.4% | 1.56% | 1.7% | 115/159 | 51.53% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 31.86% | 0.27% | 0.41% | 115/159 | 32.76% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 31.73% | -3.03% | -3.45% | 119/159 | 38.65% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 32.86% | -2.73% | 3.01% | 114/159 | 52.91% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 31.9% | 3.97% | 0.41% | 119/159 | 53.74% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 31.77% | 1.61% | -2.9% | 111/159 | 6.69% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 32.72% | 0.56% | -3.14% | 115/159 | 21.74% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 33.78% | -2.78% | 10.09% | 104/159 | 54.47% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 30.69% | -7.16% | -1.87% | 125/159 | 55.21% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 31.27% | -8.98% | -3.9% | 110/159 | 47.01% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 32.54% | -9.34% | -6.36% | 118/159 | 47.45% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 34.75% | -14.08% | 5.14% | 98/159 | 54.21% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 33.05% | 3.14% | -3.8% | 124/159 | -144.37% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 34.36% | 6.23% | -4.28% | 103/159 | 56.57% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 35.89% | 7.63% | -11.25% | 107/159 | 54.32% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 40.44% | 16.05% | 26.2% | 82/159 | 55.5% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 32.05% | 10.55% | -0.91% | 116/159 | -1213.38% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 32.34% | 9.57% | -3.02% | 92/159 | 55.47% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 33.35% | 9.68% | -4.31% | 96/159 | 55.47% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 34.85% | 10.09% | 20.22% | 87/159 | 51.37% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 28.99% | 10.97% | -1.78% | 120/159 | -205.91% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 29.51% | 12.81% | -2.92% | 91/159 | 54.25% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 30.4% | 14.17% | -3.95% | 93/159 | 53.68% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 31.65% | 12.43% | 21.18% | 85/159 | 54.19% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 26.12% | 7.61% | -0.16% | 112/159 | 52.58% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 26.16% | 3.7% | -1.75% | 87/159 | 49.32% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 26.63% | 0.81% | -5.42% | 88/159 | 48.02% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 28.15% | -0.39% | 15.99% | 67/159 | 46.89% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 24.27% | 1.24% | -3.79% | 101/159 | 48.44% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 25.23% | 3.62% | -4.48% | 69/159 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 26.41% | 4.9% | -6.55% | 76/159 | 46.2% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 28.27% | 4.1% | 17.89% | 60/159 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 23.98% | 9.08% | -1.52% | 90/159 | 46.24% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 24.35% | 9.46% | -3.31% | 65/159 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
| 2015-06-30 | 25.18% | 7.73% | -7.26% | 67/159 | 45.36% | 贝达药业 | 96.95% | 行业排名> |
| 2015-03-31 | 27.15% | 12.38% | 23.53% | 54/159 | 43.46% | 舒泰神 | 94.4% | 行业排名> |